Hikma Acquires Stake in Chinese API Manufacturer

Hikma Pharmaceuticals (London) says it has acquired a significant minority interest in Hubei Haosun Pharmaceutical through the subscription of new equity for $5 million. Hubei Haosun, a privately held company that develops and manufactures niche, difficult to make active pharmaceutical ingredients (APIs) with a specialization in oncology APIs, is located in the Gedian Economical Development Zone in Hubei province, China. Hubei Haosun operates a U.S. FDA and European Union approved facility and its product portfolio and development pipeline, which covers a range...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers